Shares of NovoCure Limited (NVCR) are falling about 18 percent on Thursday morning after the company announced that its Phase 3 TRIDENT trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival for patients in the intent-to-treat population who initiated Tumor Treating Fields therapy at the start of chemoradiation.
Shares of the company slipped 18.16 percent to $14.51 on the Nasdaq, compared with the previous closing price of $17.85. The stock has traded in a 52-week range of $9.82 to $18.92.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.